1. Home
  2. VAC vs MESO Comparison

VAC vs MESO Comparison

Compare VAC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marriott Vacations Worldwide Corporation

VAC

Marriott Vacations Worldwide Corporation

HOLD

Current Price

$68.85

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$14.62

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VAC
MESO
Founded
1984
2004
Country
United States
Australia
Employees
N/A
81
Industry
Real Estate
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.2B
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
VAC
MESO
Price
$68.85
$14.62
Analyst Decision
Buy
Strong Buy
Analyst Count
9
1
Target Price
$68.56
N/A
AVG Volume (30 Days)
637.5K
229.6K
Earning Date
05-27-2026
01-01-0001
Dividend Yield
4.71%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,032,000,000.00
N/A
Revenue This Year
$54.41
$633.98
Revenue Next Year
$2.06
$29.51
P/E Ratio
N/A
N/A
Revenue Growth
1.31
N/A
52 Week Low
$44.58
$9.61
52 Week High
$86.33
$21.50

Technical Indicators

Market Signals
Indicator
VAC
MESO
Relative Strength Index (RSI) 68.33 32.47
Support Level $63.42 $14.53
Resistance Level $74.88 $16.32
Average True Range (ATR) 3.36 0.52
MACD 1.47 -0.23
Stochastic Oscillator 78.35 27.85

Price Performance

Historical Comparison
VAC
MESO

About VAC Marriott Vacations Worldwide Corporation

Marriott Vacations Worldwide Corp functions in the United States leisure industry. It owns and manages a cluster of resorts and accommodation facilities under trademarks like Marriott Vacation Club, Grand Residencies, and The Ritz-Carlton Destination Club predominantly in the United States. Some of its properties are also spread across Europe and Asia Pacific. Marriott's majority revenue components include the sale of vacation ownership products such as luxurious vacation packages. In addition, it offers purchase money financing to the end users of its core services. The company operates in two reportable segments: Vacation Ownership and Exchange & Third-Party Management. The majority of revenue is derived from the Vacation Ownership segment.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: